Connects life-science researchers at biopharmaceutical, diagnostic, and government or academic organizations with human biospecimens and associated data through an online marketplace.
10-K for FY2025, filed Apr 1, 2026iSpecimen is technology-driven company founded to address a critical challenge: how to connect life science researchers who need human…View ↗
The iSpecimen Marketplace brings new capabilities to a highly fragmented and inefficient biospecimen procurement market. Our technology…View ↗
Our CustomersView ↗
Researchers pay iSpecimen for specimens sourced from hospitals, laboratories, and other supply sites; iSpecimen distributes part of the revenue to the supplying organizations.
10-K for FY2025, filed Apr 1, 2026 10-K for FY2022, filed Mar 21, 2023The iSpecimen Marketplace currently supports the supply chain management and bioprocurement process for specimens and associated data. We…View ↗
The iSpecimen Marketplace currently supports the supply chain management and bioprocurement process for specimens and associated data. We…View ↗
10-K for FY2025, filed Apr 1, 2026
FY2025 revenue by product or service ↗$1.9M
10-K for FY2025, filed Apr 1, 2026
$1.9M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Specimens - contracts with customers
Sold outright
10-K for FY2025, filed Apr 1, 2026 |
90%
FY2022: 96%
|
Specimens - contracts with customers, FY2025
$1.7M Sources
|
Sold outright |
|
Shipping and other
|
10%
FY2022: 4.3%
|
Shipping and other, FY2025
$194K Sources
|
Biopharmaceutical companies, in vitro diagnostic companies, and government and academic institutions use the online marketplace to search for and order specimens; healthcare providers supply them.
10-K for FY2025, filed Apr 1, 2026Our CustomersView ↗
The iSpecimen Marketplace brings new capabilities to a highly fragmented and inefficient biospecimen procurement market. Our technology…View ↗
The platform is built upon a robust healthcare data set comprised of information about available specimens and research subjects, which…View ↗
10-K for FY2025, filed Apr 1, 2026
For the year ended December 31, 2025, one customer (Customer A) accounted for approximately 19.57% of the Company’s total revenues. For the…View ↗
No. It lost $10.5M in FY2025.
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.4MView ↗
10-Q for Q2 FY2026, filed Aug 14, 2026
Open tableView ↗
8-K, filed Nov 5, 2026
The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. On the Closing Date, the…View ↗
8-K, filed Sep 10, 2026
On September 8, 2026, iSpecimen Inc. (the “Company”) received a letter dated September 8, 2026 (the “Deficiency Letter”) from the Listing…View ↗
8-K, filed Aug 31, 2026
On August 26, 2026, Katharyn Field informed the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) of her decision to…View ↗
New sequencing initiative
The latest report adds a Next Generation Sequencing initiative to the adjacent opportunities it is pursuing, alongside clinical-trial recruitment, data products, and software subscriptions.
10-K for FY2022, filed Mar 21, 2023 10-K for FY2025, filed Apr 1, 2026As we continue to ingest and generate more data, there are additional business opportunities to leverage our platform and continue to…View ↗
As we continue to ingest and generate more data, there are additional business opportunities to leverage our platform and continue to…View ↗
Competes with Discovery Life Sciences, StemExpress, and Science Exchange
10-K for FY2025, filed Apr 1, 2026Specimen providers (e.g. Discovery Life Sciences and StemExpress) maintain internal biobanks and enable researchers to search online for…View ↗
Loading...